Ensaculin Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414026

CAS#: 155773-59-4 (free base)

Description: Ensaculin Free Base is a neuronal activator.


Chemical Structure

img
Ensaculin Free Base
CAS# 155773-59-4 (free base)

Theoretical Analysis

MedKoo Cat#: 414026
Name: Ensaculin Free Base
CAS#: 155773-59-4 (free base)
Chemical Formula: C26H32N2O5
Exact Mass: 452.23
Molecular Weight: 452.550
Elemental Analysis: C, 69.01; H, 7.13; N, 6.19; O, 17.68

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 155773-59-4 (free base)   209969-60-8 (HCl)  

Synonym: Ensaculin Free Base

IUPAC/Chemical Name: 7-Methoxy-6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propoxy)-3,4-dimethylcoumarin

InChi Key: FQELZLMTAPJJOL-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H32N2O5/c1-18-19(2)26(29)33-23-17-24(31-4)25(16-20(18)23)32-15-7-10-27-11-13-28(14-12-27)21-8-5-6-9-22(21)30-3/h5-6,8-9,16-17H,7,10-15H2,1-4H3

SMILES Code: O=C1OC2=C(C=C(OCCCN3CCN(C4=CC=CC=C4OC)CC3)C(OC)=C2)C(C)=C1C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 452.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hoerr R, Noeldner M. Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment. CNS Drug Rev. 2002 Summer;8(2):143-58. doi: 10.1111/j.1527-3458.2002.tb00220.x. PMID: 12177685; PMCID: PMC6741668.

2: Teismann P, Ferger B. Comparison of the novel drug Ensaculin with MK-801 on the reduction of hydroxyl radical production in rat striatum after local application of glutamate. Brain Res. 2000 Feb 28;857(1-2):165-71. doi: 10.1016/s0006-8993(99)02395-1. PMID: 10700564.

3: Teismann P, Ferger B. Effects of ensaculin on dopamine metabolite levels and K(+)-induced glutamate release. Eur J Pharmacol. 2000 Jun 16;398(2):247-50. doi: 10.1016/s0014-2999(00)00290-9. PMID: 10854836.

4: Hudáčová M, Hamuľaková S, Konkoľová E, Jendželovský R, Vargová J, Ševc J, Fedoročko P, Soukup O, Janočková J, Ihnatova V, Kučera T, Bzonek P, Novakova N, Jun D, Junova L, Korábečný J, Kuča K, Kožurková M. Synthesis of New Biscoumarin Derivatives, In Vitro Cholinesterase Inhibition, Molecular Modelling and Antiproliferative Effect in A549 Human Lung Carcinoma Cells. Int J Mol Sci. 2021 Apr 7;22(8):3830. doi: 10.3390/ijms22083830. PMID: 33917200; PMCID: PMC8068036.

5: Knauber J, Müller WE. Anseculin improves passive avoidance learning of aged mice. Pharmacol Res. 2003 Mar;47(3):225-33. doi: 10.1016/s1043-6618(02)00311-0. PMID: 12591018.

6: Reisner E, Nöldner M, Rossner S, Chatterjee SS, Bigl V, Schliebs R. Acute effect of KA-672, a putative cognitive enhancer, on neurotransmitter receptor binding in mouse brain. Neurosci Lett. 1999 Oct 29;274(3):187-90. doi: 10.1016/s0304-3940(99)00725-9. PMID: 10548421.

7: Winter JC, Helsley SE, Rabin RA. The discriminative stimulus effects of KA 672, a putative cognitive enhancer: evidence for a 5-HT1A component. Pharmacol Biochem Behav. 1998 Jul;60(3):703-7. doi: 10.1016/s0091-3057(98)00043-4. PMID: 9678654.

8: Sourgens H, Hoerr R, Biber A, Steinbrede H, Derendorf H. KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers. J Clin Pharmacol. 1998 Apr;38(4):373-81. doi: 10.1002/j.1552-4604.1998.tb04438.x. PMID: 9590466.

9: Teismann P, Ferger B. In vivo effects of the putative cognitive enhancer KA-672.HCl in comparison with 8-hydroxy-2-(di-N-propylamino) tetralin and haloperidol on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Feb;24(2):337-48. doi: 10.1016/s0278-5846(99)00088-3. PMID: 10800755.

10: Lishko PV, Maximyuk OP, Chatterjee SS, Nöldner M, Krishtal OA. The putative cognitive enhancer KA-672.HCl is an uncompetitive voltage-dependent NMDA receptor antagonist. Neuroreport. 1998 Dec 21;9(18):4193-7. doi: 10.1097/00001756-199812210-00035. PMID: 9926872.